Global Liposome Injection 麻豆原创 Growth 2025-2031

Publication ID:

LPI03258663

Publication Date:

March 5, 2025

Pages:

117

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Liposome Injection market size is predicted to grow from US$ 721 million in 2025 to US$ 996 million in 2031; it is expected to grow at a CAGR of 5.5% from 2025 to 2031.
Liposomes are lipid microcapsules composed of an amphiphilic lipid bilayer (monolayer) and/or a series of concentric discontinuous aqueous compartments separated by a series of multiple amphiphilic bilayers. In liposome drugs, the drug is contained in liposomes. In general, water-soluble drugs are often encapsulated in the aqueous compartment, and lipophilic drugs are encapsulated in the lipid bilayer of the liposome.
According to the "Global Use of Medicines 2023" released by the IQVIA Institute, the global drug expenditure in 2022 will be approximately US$1.48 trillion (excluding costs related to COVID vaccines and therapies), and it is predicted that it will grow at a rate of 3%-6% in the next few years. In terms of regional development trends, high-income countries such as Western Europe, North America, and Japan are expected to experience slower growth in the next few years due to already high per capita usage, while growth markets such as Asia, Latin America, and Eastern Europe are expected to grow strongly. In terms of drug expenditure, China"s drug expenditure in 2022 will be about 166 billion US dollars. It is expected that the expenditure on medicines will only increase in the next few years: From the perspective of demand, the trend of population aging, the increase of residents鈥� wealth and the improvement of health awareness will drive the demand for medicines; from the perspective of national strategy, in 2016 , the State Council issued the "Healthy China 2030" Planning Outline, and "Healthy China" has risen to a national strategy; from the perspective of industry policy, it has experienced the uncertainty brought about by the initial stage of medical reform, the implementation of the centralized procurement policy and the expansion of the drug reimbursement catalog The update will gradually achieve a dynamic balance of multiple goals such as promoting innovation, stabilizing supply, and reducing the burden on the masses. Global Use of Medicines 2023 shows that, based on net ex-factory prices, the U.S. market will spend about $62.9 billion on medicines in 2022. Overall growth slows as the Inflation Reduction Act (IRA) spends $64 billion to reduce prescription drug prices, and the adoption of new treatments is expected to increase over the next few years, with ex-factory discounts and rebates in the drug pipeline , the impact of patent expiration, and generic or biosimilar competition will also affect the U.S. pharmaceutical market.
The 鈥淟iposome Injection Industry Forecast鈥� looks at past sales and reviews total world Liposome Injection sales in 2024, providing a comprehensive analysis by region and market sector of projected Liposome Injection sales for 2025 through 2031. With Liposome Injection sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Liposome Injection industry.
This Insight Report provides a comprehensive analysis of the global Liposome Injection landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Liposome Injection portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Liposome Injection market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Liposome Injection and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Liposome Injection.
This report presents a comprehensive overview, market shares, and growth opportunities of Liposome Injection market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Doxorubicin Hydrochloride Liposome Injection
Mitoxantrone Hydrochloride Liposome Injection
Irinotecan Hydrochloride Liposome Injection
Others
Segmentation by Application:
Malignant Tumor Treatment
Infection Treatment
Post-operative Pain Relief
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
CSPC
Luye Pharma
Fudan Zhangjiang
Nanjing Cisco
Qilu Pharmaceutical
Sichuan Kelun
Modern Medicine
Eudinamis
Indiamart
Getwelloncology
Polymun
Key Questions Addressed in this Report
What is the 10-year outlook for the global Liposome Injection market?
What factors are driving Liposome Injection market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Liposome Injection market opportunities vary by end market size?
How does Liposome Injection break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Liposome Injection Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Liposome Injection by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Liposome Injection by Country/Region, 2020, 2024 & 2031
2.2 Liposome Injection Segment by Type
2.2.1 Doxorubicin Hydrochloride Liposome Injection
2.2.2 Mitoxantrone Hydrochloride Liposome Injection
2.2.3 Irinotecan Hydrochloride Liposome Injection
2.2.4 Others
2.3 Liposome Injection Sales by Type
2.3.1 Global Liposome Injection Sales 麻豆原创 Share by Type (2020-2025)
2.3.2 Global Liposome Injection Revenue and 麻豆原创 Share by Type (2020-2025)
2.3.3 Global Liposome Injection Sale Price by Type (2020-2025)
2.4 Liposome Injection Segment by Application
2.4.1 Malignant Tumor Treatment
2.4.2 Infection Treatment
2.4.3 Post-operative Pain Relief
2.4.4 Others
2.5 Liposome Injection Sales by Application
2.5.1 Global Liposome Injection Sale 麻豆原创 Share by Application (2020-2025)
2.5.2 Global Liposome Injection Revenue and 麻豆原创 Share by Application (2020-2025)
2.5.3 Global Liposome Injection Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Liposome Injection Breakdown Data by Company
3.1.1 Global Liposome Injection Annual Sales by Company (2020-2025)
3.1.2 Global Liposome Injection Sales 麻豆原创 Share by Company (2020-2025)
3.2 Global Liposome Injection Annual Revenue by Company (2020-2025)
3.2.1 Global Liposome Injection Revenue by Company (2020-2025)
3.2.2 Global Liposome Injection Revenue 麻豆原创 Share by Company (2020-2025)
3.3 Global Liposome Injection Sale Price by Company
3.4 Key Manufacturers Liposome Injection Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Liposome Injection Product Location Distribution
3.4.2 Players Liposome Injection Products Offered
3.5 麻豆原创 Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 麻豆原创 M&A Activity & Strategy
4 World Historic Review for Liposome Injection by Geographic Region
4.1 World Historic Liposome Injection 麻豆原创 Size by Geographic Region (2020-2025)
4.1.1 Global Liposome Injection Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Liposome Injection Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Liposome Injection 麻豆原创 Size by Country/Region (2020-2025)
4.2.1 Global Liposome Injection Annual Sales by Country/Region (2020-2025)
4.2.2 Global Liposome Injection Annual Revenue by Country/Region (2020-2025)
4.3 Americas Liposome Injection Sales Growth
4.4 APAC Liposome Injection Sales Growth
4.5 Europe Liposome Injection Sales Growth
4.6 Middle East & Africa Liposome Injection Sales Growth
5 Americas
5.1 Americas Liposome Injection Sales by Country
5.1.1 Americas Liposome Injection Sales by Country (2020-2025)
5.1.2 Americas Liposome Injection Revenue by Country (2020-2025)
5.2 Americas Liposome Injection Sales by Type (2020-2025)
5.3 Americas Liposome Injection Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Liposome Injection Sales by Region
6.1.1 APAC Liposome Injection Sales by Region (2020-2025)
6.1.2 APAC Liposome Injection Revenue by Region (2020-2025)
6.2 APAC Liposome Injection Sales by Type (2020-2025)
6.3 APAC Liposome Injection Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Liposome Injection by Country
7.1.1 Europe Liposome Injection Sales by Country (2020-2025)
7.1.2 Europe Liposome Injection Revenue by Country (2020-2025)
7.2 Europe Liposome Injection Sales by Type (2020-2025)
7.3 Europe Liposome Injection Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Liposome Injection by Country
8.1.1 Middle East & Africa Liposome Injection Sales by Country (2020-2025)
8.1.2 Middle East & Africa Liposome Injection Revenue by Country (2020-2025)
8.2 Middle East & Africa Liposome Injection Sales by Type (2020-2025)
8.3 Middle East & Africa Liposome Injection Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Liposome Injection
10.3 Manufacturing Process Analysis of Liposome Injection
10.4 Industry Chain Structure of Liposome Injection
11 麻豆原创ing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Liposome Injection Distributors
11.3 Liposome Injection Customer
12 World Forecast Review for Liposome Injection by Geographic Region
12.1 Global Liposome Injection 麻豆原创 Size Forecast by Region
12.1.1 Global Liposome Injection Forecast by Region (2026-2031)
12.1.2 Global Liposome Injection Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Liposome Injection Forecast by Type (2026-2031)
12.7 Global Liposome Injection Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 CSPC
13.1.1 CSPC Company Information
13.1.2 CSPC Liposome Injection Product Portfolios and Specifications
13.1.3 CSPC Liposome Injection Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 CSPC Main Business Overview
13.1.5 CSPC Latest Developments
13.2 Luye Pharma
13.2.1 Luye Pharma Company Information
13.2.2 Luye Pharma Liposome Injection Product Portfolios and Specifications
13.2.3 Luye Pharma Liposome Injection Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Luye Pharma Main Business Overview
13.2.5 Luye Pharma Latest Developments
13.3 Fudan Zhangjiang
13.3.1 Fudan Zhangjiang Company Information
13.3.2 Fudan Zhangjiang Liposome Injection Product Portfolios and Specifications
13.3.3 Fudan Zhangjiang Liposome Injection Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Fudan Zhangjiang Main Business Overview
13.3.5 Fudan Zhangjiang Latest Developments
13.4 Nanjing Cisco
13.4.1 Nanjing Cisco Company Information
13.4.2 Nanjing Cisco Liposome Injection Product Portfolios and Specifications
13.4.3 Nanjing Cisco Liposome Injection Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Nanjing Cisco Main Business Overview
13.4.5 Nanjing Cisco Latest Developments
13.5 Qilu Pharmaceutical
13.5.1 Qilu Pharmaceutical Company Information
13.5.2 Qilu Pharmaceutical Liposome Injection Product Portfolios and Specifications
13.5.3 Qilu Pharmaceutical Liposome Injection Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Qilu Pharmaceutical Main Business Overview
13.5.5 Qilu Pharmaceutical Latest Developments
13.6 Sichuan Kelun
13.6.1 Sichuan Kelun Company Information
13.6.2 Sichuan Kelun Liposome Injection Product Portfolios and Specifications
13.6.3 Sichuan Kelun Liposome Injection Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Sichuan Kelun Main Business Overview
13.6.5 Sichuan Kelun Latest Developments
13.7 Modern Medicine
13.7.1 Modern Medicine Company Information
13.7.2 Modern Medicine Liposome Injection Product Portfolios and Specifications
13.7.3 Modern Medicine Liposome Injection Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Modern Medicine Main Business Overview
13.7.5 Modern Medicine Latest Developments
13.8 Eudinamis
13.8.1 Eudinamis Company Information
13.8.2 Eudinamis Liposome Injection Product Portfolios and Specifications
13.8.3 Eudinamis Liposome Injection Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Eudinamis Main Business Overview
13.8.5 Eudinamis Latest Developments
13.9 Indiamart
13.9.1 Indiamart Company Information
13.9.2 Indiamart Liposome Injection Product Portfolios and Specifications
13.9.3 Indiamart Liposome Injection Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Indiamart Main Business Overview
13.9.5 Indiamart Latest Developments
13.10 Getwelloncology
13.10.1 Getwelloncology Company Information
13.10.2 Getwelloncology Liposome Injection Product Portfolios and Specifications
13.10.3 Getwelloncology Liposome Injection Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Getwelloncology Main Business Overview
13.10.5 Getwelloncology Latest Developments
13.11 Polymun
13.11.1 Polymun Company Information
13.11.2 Polymun Liposome Injection Product Portfolios and Specifications
13.11.3 Polymun Liposome Injection Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Polymun Main Business Overview
13.11.5 Polymun Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.